Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour [9]

Gut

Volumn 56, Issue 7, 2007, Pages 1025-1026

  Grabellus, Florian ^a   Ebeling, Peter ^a   Worm, Karl ^a   Sheu, Sien Yi ^a   Antoch, Gerald ^a   Frilling, Andrea ^a   Schmid, Kurt W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB;

ADULT; CANCER INHIBITION; CARCINOGENESIS; CASE REPORT; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; INTERSTITIAL CELL OF CAJAL; LETTER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTO ONCOGENE; TREATMENT OUTCOME;

BASE SEQUENCE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MIDDLE AGED; NIACINAMIDE; PIPERAZINES; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 34347271967     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.115923     Document Type: Letter

References (9)

1. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT]: gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal rumors. Science 1998;279:577-80.
3. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-90.
4. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7.
5. Benjamin R, Schöffski P, Hartmann JT, et al. Initial results of a multicenter single arm phase 2 study of AMG 706, an oral multi-kinase inhibitor, for the treatment of advanced imatinib-resistant gastrointestinal stromal tumors (GIST). Oral presentation No 641 CTOS 12th Annual Meeting 2006. http://www.ctos.org (accessed 3 March 2007).
6. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006;12:1743-9.
7. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005;6:249-51.
8. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
9. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.